Holen Sie sich die Stockscreener-App
12.67
2.54%
-0.33
Schlusskurs vom Vortag:
$13.00
Offen:
$13
24-Stunden-Volumen:
2.31M
Relative Volume:
0.49
Marktkapitalisierung:
$807.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-145.21M
KGV:
-5.5087
EPS:
-2.3
Netto-Cashflow:
$-140.12M
1W Leistung:
-0.78%
1M Leistung:
+38.32%
6M Leistung:
-67.13%
1J Leistung:
-75.57%
1-Tages-Spanne:
$12.43
$13.19
1-Wochen-Bereich:
$12.43
$13.99
52-Wochen-Spanne:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Vergleichen Sie MLTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
12.67 | 921.02M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-09-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-09-30 | Herabstufung | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Herabstufung | Stifel | Buy → Hold |
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
HC Wainwright Lowers MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $26.00 - Defense World
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - Morningstar
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX - GlobeNewswire Inc.
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
MoonLake Immunotherapeutics’ (MLTX) Reported Phase 3 Trial - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionMLTX - MarketScreener
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - PR Newswire
Moonlake Immunotherapeutics stock price target lowered to $26 at H.C. Wainwright - Investing.com India
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - Nasdaq
MoonLake Immunotherapeutics Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMLTX - Stock Titan
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Burned by MoonLake Immunotherapeutics? Contact Levi & Korsinsky to SueWallSt And Fight Back - ACCESS Newswire
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join - GlobeNewswire
MLTX INVESTORS: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses to Contact the Firm Before the Imminent December 15 Securities Class Action Deadline - MarketScreener
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - FinancialContent
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MLTX LAWSUIT ALERT: The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
MLTX LEGAL REMINDER: MoonLake Immunotherapeutics Faces Securities Allegations over Drug Trial Results -- Investors Alerted to Contact BFA Law before December 15 - ACCESS Newswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake - GlobeNewswire
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
The Gross Law Firm Notifies MoonLake Immunotherapeutics - GlobeNewswire
MLTX LAWSUIT: MoonLake Immunotherapeutics Investors are Notified to Contact BFA Law about the Filed Securities Fraud Class Action and Important December 15 Deadline - Newsfile
Deadline Alert: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - Newsfile
Holdings of MoonLake Immunotherapeutics (MLTX) are aligned with the stars - Setenews
MLTX CLASS NOTICE: BFA Law Alerts MoonLake Immunotherapeutics Investors of the Pending Securities Fraud Class Action and Upcoming December 15 Deadline - Newsfile
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - PR Newswire
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out - Yahoo Finance
Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones - news.stocktradersdaily.com
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Over Securities ViolationsContact Levi & Korsinsky Today - Newsfile
MLTX DEADLINE REMINDER: MoonLake Immunotherapeutics 90% Stock Drop Triggers Securities Fraud Class ActionInvestors Urged to Contact BFA Law by December 15 - ACCESS Newswire
MLTX MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - MarketScreener
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - GlobeNewswire
MLTX DEADLINE REMINDER: Berger Montague Reminds MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Important Class Action Lawsuit Deadline - Eastern Progress
MoonLake Immunotherapeutics Stock: Ignore The Panic, Catch The Upside (NASDAQ:MLTX) - Seeking Alpha
Bragar Eagel & Squire, P.C. Reminds Stockholders of aTyr, - GlobeNewswire
MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph
MoonLake Immunotherapeutics Sued for Securities Law - GlobeNewswire
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 15, 2025 Deadline - Newsfile
MLTX STOCK LOSS: MoonLake Immunotherapeutics Faces - GlobeNewswire
MLTX Stockholders Have Opportunity to Lead MoonLake Immunotherapeutics Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
United StatesMintz Advises On MoonLake Immunotherapeutics’ $75 Million Offering - Mondaq
Quantitative breakdown of MoonLake Immunotherapeutics recent moveStock Surge & Risk Adjusted Buy/Sell Alerts - newser.com
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):